We are thrilled to announce that RitSight, our 0.22% riboflavin ophthalmic solution for corneal cross-linking, has been granted the CE Certificate in conformity with the Medical Device Regulation (MDR)!
This certification marks a significant step forward in advancing corneal cross-linking treatments, ensuring the highest standards of safety, efficacy, and quality for patients with keratoconus and other corneal disorders, including iatrogenic corneal ectasia, pellucid marginal degeneration, bullous keratopathy and infectious keratitis.
RitSight is designed and manufactured to optimize corneal cross-linking procedures by:
✔️ Offering precise dosing and enhanced bioavailability.
✔️ Supporting personalized treatments through theranostic guided UV therapy.
✔️ Meeting the rigorous requirements of the MDR, reflecting our commitment to innovation and patient care.
We are proud of this achievement, which reinforces our mission to provide cutting-edge solutions for eye health and to support ophthalmologists in delivering the best possible outcomes for their patients.